Anthropic's science lab this week described a novel enzyme that binds and cuts DNA at repeat arrays, short sequences that copy themselves over and over in a genome (Forbes, September 25). CRISPR systems work because bacteria store snippets of past viral DNA in their own genome as a memory bank, then use an enzyme like Cas9 to match that stored snippet against incoming viral DNA and cut it. This new enzyme appears to do something related but not identical: it recognizes DNA repeat arrays, the stuttering sequences that show up when a short piece of DNA copies itself in place, and cuts there. The stage is benchtop, a computational and biochemical find in existing genomic data rather than a therapy or even a demonstrated editing tool.

The reason this matters has nothing to do with the company that found it. Every gene-editing tool now in clinics, including CRISPR Therapeutics' ANGPTL3 edit that cut cholesterol 52% in a single dose (Wang Report, September 23), descends from one bacterial defense system discovered by accident in yogurt cultures. A second, mechanistically distinct enzyme family that reads repeat structure rather than stored viral memory would give editing designers a different chassis to build on, useful for target sequences CRISPR handles poorly. Anthropic's paper describes the enzyme's binding behavior; it has not yet been shown to make a precise, programmable cut the way Cas9 does. The next gate is a demonstration that this enzyme can be redirected to cut a chosen sequence rather than just its natural repeat targets, the step that would turn a discovery into a tool.